Bensalem, PA (PRWEB) February 11, 2011
Xybion Corporation, a leading provider of preclinical R&D solutions, announced today that Chengdu Frontier BioSciences Co., a global contract research organization (CRO) has licensed Xybion’s Pristima suite to support end-to-end preclinical data management processes. Chengdu Frontier BioSciences has also engaged Xybion’s Professional Services team to deliver full implementation including installation, instrument interfacing, training, and validation. Chengdu Frontier BioSciences will be leveraging Pristima’s powerful capabilities including Colony Management, General Toxicology, Clinical Pathology and Pathology as part of its strategy to improve the entire safety assess process and to expand the wide variety of services Frontier BioSciences provides its client community.
Frontier’s CEO, Dr. Dong Xie, commented, “We are committed to continuously improving our accuracy and efficiency. As such, the implementation of Pristima system will help elevate our level of performance, and ensure efficient delivery of data to our sponsors. This decision is a key element to our goal of becoming a preeminent service-provider in the area of preclinical drug development.” Further commenting, Frontier’s COO, Dr. Li Tian, remarked, “We selected Xybion after assessing the market, extensive consultation with our clients and industry experts, and in-depth familiarization of the software tools. The system is very functional and user-friendly, requiring minimal training, and is supported by a world-class team.”
Dr. Pradip Banerjee, Xybion’s CEO, stated, “We are thrilled to add Chengdu Frontier BioSciences to Xybion’s client community and to expand our global footprint. The Chinese drug development market is extremely active and full of promise so it is important that Xybion develops clients and partners in this market.” Dr. Banerjee continued, “As a system that operates equally in Mandarin or English and is enterprise-grade application suite, we believe Pristima is the premier solution available to the China research and development market.”
Chengdu Frontier BioSciences, with its diverse services and high quality standards, selected Xybion’s Pristima solution to best meet its objectives in delivering high quality studies and final reports. The selection of Pristima was the result of a comprehensive market assessment and consultation with Chengdu Frontier BioSciences’clients and industry experts. Chengdu Frontier BioSciences selected Xybion based on several key factors including Xybion’s global market presence, strong preclinical data management credentials, and comprehensive professional service offerings. With its global presence, Xybion will provide Chengdu BioSciences with both remote and on-site implementation services to assure a successful deployment and a quick return on investment.